PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab
Sponsor: Ottawa Hospital Research Institute
Collaborators: Ontario Institute for Cancer Research